Kymera Therapeutics Inc
$ 91.01
2.92%
24 Feb - close price
- Market Cap 7,074,314,000 USD
- Current Price $ 91.01
- High / Low $ 91.99 / 87.37
- Stock P/E N/A
- Book Value 13.19
- EPS -3.60
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.32 %
- 52 Week High 103.00
- 52 Week Low 19.45
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$116.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-11 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 | -0.7 |
| Estimated EPS | -0.7945 | -0.8613 | -0.83 | -0.73 | -0.7882 | -0.84 | -0.68 | -0.73 | -0.4 | -0.64 | -0.71 | -0.68 |
| Surprise | 0.7945 | -0.0787 | -0.12 | -0.09 | -0.1018 | 0.02 | 0.1 | 0.11 | 0.15 | -0.26 | 0.04 | -0.02 |
| Surprise Percentage | 100% | -9.1374% | -14.4578% | -12.3288% | -12.9155% | 2.381% | 14.7059% | 15.0685% | 37.5% | -40.625% | 5.6338% | -2.9412% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-02-24 11:51:57
Kymera Therapeutics (NASDAQ: KYMR) is scheduled to participate in several investor conferences and fireside chats throughout March 2026, including major healthcare events hosted by TD Cowen, UBS, Leerink, Jefferies, and Barclays. The company will discuss its clinical-stage programs and corporate updates, focusing on its oral immunology pipeline and 2026 objectives. Webcasts of these presentations will be available for investors on Kymera's website.
2026-02-24 11:51:57
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in March. These events include fireside chats at the TD Cowen 46th Annual Healthcare Conference, Leerink Partners Global Healthcare Conference, and Barclays 28th Annual Global Healthcare Conference, along with participation in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit. The company, focused on targeted protein degradation, will provide live webcasts of presentations on its website.
2026-02-23 19:28:37
Kymera Therapeutics (KYMR) shares surged 130% over the past year, outperforming the S&P 500, following a significant investment by Baker Bros. Advisors. The firm purchased over 2 million additional shares, valued at an estimated $135.45 million, boosting its immunology bet on Kymera. Kymera, a clinical-stage biotechnology company, is advancing its pipeline of targeted protein degradation therapies, with lead programs in immunology nearing key clinical readouts and a strong financial runway.
2026-02-23 12:16:09
Patient Square Capital LP significantly reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 33.9% in the third quarter, selling 47,408 shares. Despite this reduction, Kymera Therapeutics remains the 12th largest holding for Patient Square Capital LP, making up approximately 1.4% of its portfolio. Other institutional investors like PNC Financial Services Group Inc., Bessemer Group Inc., and Osaic Holdings Inc. increased their positions in Kymera Therapeutics, while several analysts have issued "Buy" or "Strong Buy" ratings for the stock, with an average target price of $117.00.
2026-02-19 17:27:05
BofA Securities has upgraded Kymera Therapeutics (KYMR) to a "Buy" rating from "Neutral" and raised its price target to $51 per share, indicating significant upside potential for the stock. This upgrade is driven by increased confidence in the company's oncology pipeline, particularly KT-611, an IRAK4 degrader. The analyst's strong convictions are based on improved preclinical data and a re-evaluation of market opportunities.
2026-02-19 11:57:46
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced it will report its fourth quarter and full year 2025 financial results on February 26, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on that day to discuss the results. Interested parties can register via a provided link or visit the Investors section of Kymera's website.
